Vaccinia Capping Enzyme
7-methylguanylate cap structures (Cap-0) are essential for efficient translation of in vitro-transcribed RNA in eukaryotic expression systems. Vaccinia Capping Enzyme provides all the components necessary to add Cap-0 structures to the 5′ ends of uncapped RNA. RNA transcripts can be capped in less than one hour in the presence of the capping enzyme, reaction buffer, GTP, and a methyl donor.
7-methylguanylate cap structures (Cap-0) are essential for efficient translation of in vitro-transcribed RNA in eukaryotic expression systems. Vaccinia Capping Enzyme provides all the components necessary to add Cap-0 structures to the 5′ ends of uncapped RNA. RNA transcripts can be capped in less than one hour in the presence of the capping enzyme, reaction buffer, GTP, and a methyl donor.
The use of the Vaccinia Capping Enzyme in the same reaction with mRNA Cap 2′-O-Methyltransferase (Cat. # 2470) generates Cap-1 RNA. Cap-1 RNA has a methyl group at the 2'-O position of the first nucleotide adjacent to the cap structure at the 5´ ends of the RNA. This capping modification reduces the innate immune response to in vitro transcribed RNA when it is used in vivo.
Overview
A complete solution for enzymatic capping of in vitro-transcribed mRNAs.
- Add 7-methylguanylate cap structures (Cap-0) to the 5′ ends of uncapped RNA
- Use together with Cap 2′-O-Methyltransferase (Cat. # 2470) to generate Cap-1 RNA
- Save on reaction costs when you purchase the larger size
- Absent of nuclease activity
More Information
Applications
- Enzymatic capping of in vitro-transcribed mRNA prior to translation
- Labeling 5′ ends of mRNA
Source
Escherichia coli that harbor plasmids containing the genes for the vaccinia virus capping enzyme.
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Speed up your vaccine development with innovative technologies
Vaccines have significantly decreased the burden of infectious diseases worldwide since the development of the first vaccine more than 200 years ago that led to the eradication of smallpox. In recent years, the spread of severe infections has highlighted the critical need for the rapid development of vaccines against previously unknown pathogens to deal with pandemics such as COVID-19.
Discover how Takara Bio can help speed up your vaccine-development process.
Learn moreTakara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2024 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
